Top and Bottom Line Picture for ADMA Biologics Inc. (NASDAQ:ADMA)?

833

ADMA Biologics, Inc. (NASDAQ:ADMA), a member of Biotechnology, has a market of $45.50M.

The company has seen its stock rally between a high and a low of $-50.11% and $16.70%, respectively, over the last 12 months.

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

Recently, ADMA Biologics, Inc. (NASDAQ:ADMA) announced it signed a definitive agreement to acquire certain manufacturing and therapy-related assets from Biotest Pharmaceuticals Corporation (BPC), a wholly-owned subsidiary of Biotest AG. The transaction, subject to customary closing conditions, including shareholder approval, is expected to close during the first half of 2017.

The stock’s performance for the week is 6.71% and performance of the month is -11.41%. For the quarter, though, the stock has moved -15.98%, compared with -28.35% movement for the half-year period and -44.49% for the year. So far this year shares of ADMA Biologics, Inc. have moved -22.05%.

Various analysts have weighed on the stock of ADMA Biologics, Inc., giving it average price target of $12.17. That compares with the current price of $3.99. In terms of stock recommendation, the average analysts? recommendation on the stock is 2.00.

ADMA Biologics, Inc. stock has average volume and relative volume of 29.80K and 1.15, respectively.

The weekly volatility measure for the stock of ADMA Biologics, Inc. is 7.43%, while the monthly volatility measure stands at 7.16%.

The stock has a short float of 0.60% and short ratio of 2.28, which is a market sentiment indicator offering a hint on whether investors expect a stock to rise or fall.

ADMA Biologics, Inc. has a current ratio of 1.20 for the most recent quarter. Quick ratio for the same period is 0.80. The company has Total/Debt/Equity ratio of Total Debt/Equity – and Long Term Debt/Equity ratio -.

ADMA Biologics, Inc. has produced return on equity of 748.90% for the last 12 months, while return on investment for the same period is -110.40%. It also generated return on assets of -85.30% for the trailing 12 months.

 

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.